MSU students honored by chemistry department – Springfield News-Leader

Subscribe today for full access on your desktop, tablet, and mobile device.

Let friends in your social network know what you are reading about

The Chemistry Recognition Banquet is held annually and awards which range from fellowships to scholarships.

Try Another

Audio CAPTCHA

Image CAPTCHA

Help

CancelSend

A link has been sent to your friend's email address.

A link has been posted to your Facebook feed.

News-Leader 4:29 p.m. CT May 17, 2017

File Art(Photo: News-leader)Buy Photo

Students in the department of chemistry at Missouri State University recently attended the annual Chemistry Recognition Banquet in April.

Stephanie Dannen, a senior chemistry major from Seymour, received the Dr. Martin Research Fellowship, the Emil Lorz Memorial Scholarship and a Department of Chemistry Board of Advisers Summer Research Fellowship.

Brennon Foster, a senior biochemistry major from Springfield, received the Outstanding Physical Chemistry Student Award, the Outstanding Senior Award from the chemistry department and the Graduating Senior Award from the Midwest District of Kappa Kappa Psi.

Bryttani West, a senior chemistry major from Springfield, received the American Chemical Society Undergraduate Award in Inorganic Chemistry.

For more information visitThe College of Natural and Applied Sciences.

Read or Share this story: http://sgfnow.co/2rsm9ct

6:20

1:35

3:31

0:55

1:35

1:44

0:40

0:43

2:33

1:01

Read this article:
MSU students honored by chemistry department - Springfield News-Leader

Bonding over basketball (and chemistry) at a Target deli – ESPN

By Matt Eisenberg | May 17, 2017 espnW.com

Courtesy of Mohammed Jaljouli

Mohammed Jaljouli was surprised when his co-worker, Adele Walters, brought handwritten notes from watching a basketball game on TV. That's when he knew she was seriously interested in learning more about the sport.

Adele Walter learned everything she knows about basketball at a Target deli in Salt Lake City.

Before she found out exactly who LeBron James, Isaiah Thomas and Gordon Hayward were, she needed to know about the game itself, starting with how teams score points. So her 20-year-old coworker, Mohammed Jaljouli, explained the different types of shots: layups, 3-pointers, free throws. Then they moved on to fouls -- and that took awhile.

One night, she finished her shift, returned home and watched an NBA playoff game with her cats, two orange tabbies named Bambi and Schnicklefritz. But when she put it on, the game moved by so quickly that she didn't know why everything was happening the way it was.

So she grabbed a Sharpie and a piece of paper, used her DVR and began taking notes.

"Of all the things I hate in this life," Walter said, "I hate not understanding something."

She wrote down Pacers guard Lance Stephenson's statistics as they appeared on the screen. Based on her notes, the Cavaliers were leading the Pacers 38-34 midway through the second quarter of Game 4 in their first-round series. She jotted down the postseason's leading scorers. She copied the Western Conference bracket -- back when the Utah Jazz were down 2-1 in their first-round series against the Clippers.

Walter went back to the deli the next day, and instead of talking to Jaljouli about chemistry or "Longmire," the A&E series starring Robert Taylor, she showed Jaljouli the notes. She wanted to know more, mostly because of him.

"She paused the TV while she was watching the game and she literally wrote down everything that confused her," Jaljouli said. "That was the best part to me."

Jaljouli has loved the sport his whole life.

"He's just absolutely galvanized, and that gets my attention," Walter said.

For Jaljouli, it started with a Nintendo 64 video game. Originally from Queens, he grew up as a Miami Heat fan thanks to Dwyane Wade. Often, after finishing a 1-9 p.m. shift, he heads to the court to put up some shots with his brother.

Courtesy of Mohammed Jaljouli

Mohammed Jaljouli and Adele Walters like to talk about three things: chemistry, "Longmire" and basketball.

Walter is the mother of four children who are in their 30s and 40s. She made a point to note that one of her sons is a medic in the military and another is a doctor. "All 10 of my grandchildren are geniuses, just ask me," she said with a laugh. Her husband, Bryan, died in 2008 of a heart attack.

She says Target is "the right environment for me" and enjoys working there. She is also a science junkie. She used to work as a licensed practical nurse, and she was entranced by the documentary "Particle Fever." When she found out that Jaljouli studied chemistry at Salt Lake Community College with hopes of transferring to the University of Utah, they immediately clicked.

"Adele's a really good talker," Jaljouli said, "so she could talk about anything for hours."

Their group at the deli at Target loves thoughtful, challenging conversation, with the occasional pun. Basketball is another way for them to connect.

Walter didn't tell Jaljouli she'd be taking notes while watching the game. He thought she would watch a little bit of the game and then change the channel and put on something else. Needless to say, he was surprised to see her with a page of notes from the night before.

"That's when I knew she was really determined to learn," he said.

She paused the TV while she was watching the game and she literally wrote down everything that confused her. That was the best part to me.

Mohammed Jaljouli

Jaljouli explained who LeBron James was, mentioning his departure from and return to Cleveland. "He's a machine," Walter said.

She likes 5-foot-9 guard Isaiah Thomas and his Celtics. She's rooting for Boston not because she has any close ties to the city -- she was born in Fort Wayne, Indiana -- but rather because Robert B. Parker's books on the detectives Spenser and Hawk were set there.

Jaljouli can tell her basketball IQ is growing. For instance, she now abbreviates FT for free throws and can easily follow statistics. Plus, she remembered who Gordon Hayward was when he strolled into Target after the Jazz's season ended (though she didn't recognize him until Jaljouli pointed him out). And since Jaljouli and Walter share a bond -- no chemistry pun intended -- he makes for a good mentor.

"He's in chemistry, so he's very, very specific about everything, and I love it," Walter said. "Very clear and very detailed, and he slows it down to the pace that you understand."

It isn't the flashy dunks and highlight plays that keep Walter intrigued. It's the mental aspect of the game. How players can so easily find a rhythm and perfect their shooting motion. The physics. How 1/16th of an inch can be the difference between a shot going through the net or deflecting off the rim. The coordination. How much each player needs to process around him to set up a shot.

"It's so cerebral," she said.

Her NBA Finals prediction is Cavs-Warriors, and even after the playoffs end she plans to keep following the sport. In another week or so, she thinks she'll be able to watch a full game and understand everything that's happening. Once she grasps that knowledge, she'll have a deeper level of care.

"She loves it too now," Jaljouli said. "She's so interested, and I love that. It's teaching somebody your favorite thing in the world."

Excerpt from:
Bonding over basketball (and chemistry) at a Target deli - ESPN

Let’s Talk Lax column: Chemistry, leadership giving Beverly girls lacrosse a boost – The Salem News

The Big Panther/Little Panther program has been an on-and-off tradition employed by the Beverly High girls lacrosse program in recent seasons.

The program consists of Beverly veteran players adopting underclassmen on the team, taking them under their wing and helping them through their early high school years be it on the field, in the classrooom, or concerning matters that have nothing to do with either. Its not only a way of guidance, but of also serving as a helping hand.

The elder Panthers decided to bring the tradition back this spring as a way of building team chemistry and incorporating their younger, talented teammates into the fold after losing 12 seniors to graduation. Senior captains Maeve Blake, Amanda Rosenberger and Marita Smallman knew in order to be competitive again this season, theyd need to rely upon freshmen and sophomores developing into key contributors.

We had a lot of young talent that had big roles to play, said Blake. We knew they couldnt do that without the help of the older players, so that was our main focus.

Every youngster on the BHS varsity has an upperclassman to look to should they need help or guidance.

The veterans recalled such a program being implemented when they were freshmen by head coach Alyson Healey, but had fallen by the wayside in the past season or two.

Its been a really strong team dynamic of everybody working toward the same goals, said Blake. Were fortunate enough to have so much young talent, but with that has to come confidence. And they have to want to play for their seniors and want to play for the next three years.

The result? The Panthers have a 11-6 record in large part because of many underclassmen in the lineup stepping up and realizing their potential.

The team feel chemistry is its biggest strength; everybody cares for one another. It makes them want to make that extra play, scoop through that ground ball, or make that extra pass.

With its 10th win Tuesday (a 15-7 win at Danvers), Beverly qualified for the state tournament and matched its win total from 2016. The Panthers still have three games to play in the regular season before the Division 1 North sectional begins.

We have such a good relationship off the field; its so easy to bring that onto the field, said Smallman. So having the big Panther-little Panther with that definitely helped.

If you want proof of progress made by the Garden City underclassmen, look no further than the scoresheet. Two of the Panthers top three scorers are sophomores, with Sabrina Beaudry leading the team with 43 points. Brooke Baekey has 34, four behind senior Darcy McAuliffe for second on the squad. Baekey leads the team with 11 assists.

Beaudry, who has 41 goals, has been one of the top goal scorers on the North Shore this spring, including six tallies in Tuesdays win against Danvers. The sophomore feels the welcoming atmosphere set by the seniors have radiated throughout the team, creating a bond off the field that has translated to success on it.

When we have chemistry off the field, that definitely plays a role in our chemistry on the field, said Beaudry. And we just want to work together. Were happy for each other; even if youre not the one that makes the play, youre happy for your teammate.

There was a little sense of unknown for Beverly going into the season, with so many seniors gone and so many young players in the lineup. That is no longer the case, thanks in large part to the ownership the senior leaders took and the response it generated from the rest of the group.

We have bunch of girls who are willing to do things that dont show up on the scoreboard or in the stats book, and we try to praise that as much as possible, said Healey. And I think with our captains, theyve had to work really hard to get where they are. Its not just in this sport; theyre three-sport athletes, so they know what it takes to win games and be at the top. Im very impressed with them.

Ipswich dropped its first game last Thursday in a 11-8 setback to Newburyport in a battle of undefeated clubs. The Tigers bounced back nicely, however, scoring a season-high 20 goals their next outing against Cape Ann League rival North Reading before knocking off Division 1 heavyweight Chelmsford, 13-11, on Tuesday.

In the win against Chelmsford, Julia Glavin scored three goals and added two assists to eclipse the 100-point mark for the season, the first player on the North Shore to do so. She now has 60 goals and 104 points. Shes now the running for a rare Triple Crown, as shes tied for the area lead in goals while leading in assists (44) and points.

Peabody took the Danish Cup from crosstown rival Bishop Fenwick, scoring an 11-4 win on Saturday. After beating Methuen 10-7 on Tuesday, the Tanners have won eight straight and now stand at 12-2 . . . Kenzie Vasque notched her 100th career goal for Pingree on Monday in the Highlanders 15-3 win over Lexington Christian Academy.

Lets Talk Lax, a column on North Shore high school girls lacrosse, appears each Thursday in The Salem News during the spring sports season. Contact staff writer Pat ORourke at porourke@salemnews.com and follow him on Twitter @PatORourke_29.

||||

Read the original here:
Let's Talk Lax column: Chemistry, leadership giving Beverly girls lacrosse a boost - The Salem News

Softball: Chemistry key to Plano East’s playoff run – Star Local Media

Slowly but surely, the Plano East softball team began building momentum in pre-district play with solid pitching and an opportunistic offense.

It started district play undefeated, including a win over state-ranked Plano West. All of a sudden, East was stacking wins on top of one another. Despite a late-season loss to West, it swept Plano Senior and ended the season tied for first place in arguably the toughest district in the Metroplex.

Now, the Lady Panthers are four rounds deep in the playoffs after dispatching of Marcus, South Grand Prairie and Waco Midway. Its the schools deepest playoff run since 2012, when East advanced to the state semifinals.

That team had senior leadership and a tenured coach in Karen Kalhoefer, and while current East head coach Cindy Mosteller is certainly no rookie, East is coming off a fourth-place finish last year and has exactly one senior on this years roster.

So, where did this come from?

A couple of players point to the win over West at the beginning of the year as the moment they knew they were a good team; others look at the sweep of Plano. Still, others insist the chemistry began growing as early as pre-season.

Regardless of when the seed was planted, the Lady Panthers sport a deep, talented squad that now has a date with defending Class 6A champions Keller on Thursday.

We never really had a big head or anything coming into this season, but once we beat Plano [for the second time], that really gave us a confidence boost heading into the playoffs, said junior Gabbi Lopez. This team just has a lot more chemistry and more trust in one another. Our practices are very engaged and we work on a lot of things to prepare us for the game ahead of us.

Lopez was the teams ace last year as a sophomore, but now, with the emergence of freshman Carson Armijo, the squad has two live arms to lean on in the playoffs. Mosteller has used Armijo as her Game 1 starter in the three rounds the Lady Panthers have played in, then used Lopez to close out the opposing squad in Game 2.

Its been a remarkable combination, as Armijo relies on strikeouts, while Lopez uses an off-speed approach to pitch to contact. The result: three sweeps in three playoff rounds.

Its nice knowing that I have someone to come in relief if I need it, Lopez said. [Armijo] is a strong player all-around, and she and I have come a long way together as a duo.

I came into this season wanting to prove to others that Im a high-level player and that Im capable of competing against girls three years older than me, Armijo added. Im really grateful that Im getting the opportunity to pitch this deep into the playoffs, because now every team and batter is tough. There are no easy outs anymore.

While the pitching has been stellar, both Lopez and Armijo have had ample run support.

In six playoff games, East has scored 57 runs an average of more than nine runs per game. And, in the final two district games before the playoffs, the Lady Panthers scored nine and 12 runs, respectively.

Junior leadoff hitter Bella Konieczka said practices are very competitive, and that Mosteller lets the squad hit off of Armijo and Lopez in hopes of improving the offenses timing against other pitchers.

We work on hitting every day, and coach is always mixing up drills, Konieczka said. Hitting off live pitchers is really helpful, especially because [Armijo and Lopez] are so good. It makes hitting off other pitchers easier.

The next test for East will be Keller pitchers Dylann Kaderka, a sophomore, and senior Sarah Taylor. Like East, Keller has not yet lost a playoff game; in fact, going back to the end of the regular season, Keller has won 14 games in a row.

At the plate, the Lady Indians are led by junior Kasey Simpson, who leads the team in home runs, triples and doubles. Simpson was a star for Keller as a sophomore and committed to play softball at Iowa State once she graduates in 2018.

Game 1 is Thursday at Plano East at 5 p.m., with Game 2 set for Friday at Argyle High School at 5 p.m. A Game 3, if necessary, will be held Friday following Game 2 at Argyle.

For continued coverage of the local sports scene, follow @timothyglaze on Twitter.

Read the original:
Softball: Chemistry key to Plano East's playoff run - Star Local Media

Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment – Business Wire (press release)

VANCOUVER, British Columbia--(BUSINESS WIRE)--Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with The Centre for Drug Research and Development (CDRD), Canadas national drug development and commercialization centre, to further characterize Novelogics' internally-developed antibody immunotherapy for treating cancer.

The proprietary technology behind Novelogics innovation involves discovery and development of monoclonal antibodies that target a protein that promotes immune suppression in cancer patients. It is predicted that this new therapy could treat a broad range of cancers, and because it works with the patients own immune system, it would be safer and less toxic with fewer debilitating side-effects.

CDRD will be analyzing the technology through custom in vitro assays that will help validate and identify their lead antibody and move it towards a Phase 1 clinical trial as early as 2019. The technology has recently shown preliminary evidence of tumour inhibition in a prostate cancer model and based on results from CDRDs research, it could be expanded to other cancer models.

Novelogics President and Chief Scientific Officer Dr. Wayne Cheney stated, We are excited to introduce our novel approach to treating cancer. Unlike other immunotherapies that function by modulating, inhibiting or blocking targets, our innovative drug works by intercepting. This is a new way of limiting the immune suppressive effects of the drug target, which offers a huge opportunity to make a difference in the fight against cancer. We look forward to a successful collaboration with CDRD and are thrilled to be working with their technical team of experts and state-of-the-art biologics facility.

CDRDs Head of Biologics Dr. Ismael Samudio commented, This work with Novelogics is an exciting opportunity for CDRD to apply our scientific expertise in NK cell biology and therapeutic antibodies to a technology that has very promising pre-clinical potential. This a great example of how CDRD is partnering with Canadian life sciences companies to advance promising discoveries and transform them into validated investments and improved health outcomes. By combining our expertise and specialized infrastructure, we aim to provide critical data to advance Novelogics technology and help bring new therapeutic treatments to market.

It is anticipated that a pre-clinical candidate antibody will be selected in 2017, and that further clinical development activities will follow.

About Novelogics Biotechnology, Inc.

Novelogics Biotechnology Inc. is virtual life sciences company utilizing expertise at a variety of Contract Research labs and is dedicated to developing innovative cancer treatments that harness the power of the immune system to help eradicate tumors more naturally. Their immunotherapy concepts focus on development of antibody therapeutics and have the potential to treat multiple cancer types without the side-effects associated with traditional cancer therapies. We anticipate the technology will be well-received by larger biotechnology and pharmaceutical companies seeking novel antibody immunotherapy treatments in this exciting area of cancer drug development. Novelogics has one mission in mind we want to create better cancer treatments. http://www.novelogics.com

Novelogics Biotechnology Inc. is a privately-owned corporation operating in Vancouver, Canada.

About The Centre for Drug Research and Development (CDRD)

CDRD is Canadas national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. Canadas Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). http://www.cdrd.ca

Originally posted here:
Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment - Business Wire (press release)

The Anatomy of a Global B2B Campaign – AdAge.com

Lauren Flaherty,CA Technologies' CMO. Credit: CA Technologies

When you spy the occasional B2B ad campaign that is both surprising and relevant, veterans of the trade can't help but wonder, "Why wasn't that new 'organ' rejected by the corporate body?"

To answer this question, it helps to spend time with the top marketing surgeon (aka CMO). In the interview below, Lauren Flaherty, CMO at CA Technologies, helps dissect the strategic thinking behind CA's new global campaign, "The Modern Software Factory." In the process, her diagnosis identifies several truths that other marketers would be wise to take to heart.

Talk about your new campaign.

"The Modern Software Factory" is a way of framing how CA can help guide companies through their digital transformation. Over the last couple of years, we've been talking about the application economy and all of its promise. What we came to appreciate is that people understand it, but they struggle with how to get there. For example, customers need to be agile, they've got to get apps to market more quickly and securely, they desperately need insights from data. "The Modern Software Factory" is not a show floor for us; it's actually where we can ask customers: Where's your pain point? Where do you see your opportunity? And then we can demonstrate that we have the software that can help. [View new ads here and here.]

What was the genesis of this idea?

The genesis WAS a book written last fall by our CTO and a number CA's presales team members called "Digitally Remastered." Their insight came from years of working with customers and seeing the best practices for what we call in the book, "A Blueprint for Your Modern Software Factory." It comes from real customer data and insights, and it's a very pragmatic approach to how you proceed on the digital transformation journey.

It's a big deal for a global company to launch a new campaign like this. What were the main steps to bring the program to fruition?

We work closely with our regional colleagues to make sure that a campaign is relevant in all regions. What was fascinating was that our sales and marketing teams heard the same things from customers in every region. The customer doesn't come to the discussion saying, "I'm looking for product X, Y or Z." Instead, they say, "I need to make this happen. I have this pain point." Interestingly all of us who do global brand work struggle with adoption outside of the U.S., but there was this universal need for digital transformation. It varies by country in terms of maturity, but the need to have business be powered by software is universal.

Before we launched, we've also enabled our sales colleagues with education and training, so they're prepared to carry "The Modern Software Factory" narrative. This campaign is an articulation of our business strategy, so our ability to show CA's know-how and have a different kind of dialogue with our customers is crucial.

What were the biggest hurdles that you had to overcome in bringing this to market?

Simplification. Technology and software can get pretty geeky, pretty fast, so it was important to simplify the message to align with business outcomes, keep it customer-centric and avoid the pitfalls of speaking in code. We focused on a narrative around business value and goals, so the campaign would resonate with the targets we wanted to reach. We also developed a framework that would be globally relevant, clear and easy to understand. Once we had those elements, and coupled the voice of the customer with the device of "The Modern Software Factory," it started to click and came together quickly.

Will you be measuring impact on brand perceptions?

We measure everything! For brand, we'll look at traditional metrics around reputation management, in association with our brand familiarity and consideration. We care a lot about consideration, because that's based on our data, and is the leading indicator to what we'll see downstream in pipeline. We also look at what's happening with CA.com -- traffic, and how it spikes as we turn the faucet of content on and off, how long and where are people on the site, and more.

How about lead generation?

Underneath the brand metrics, product demand is everything here. We look at pipeline data, specifically whether we have enough opportunities by week across sales, partners, digital sales and marketing. We ask whether we're creating enough opportunity that will convert into revenue. So, we consider the full spectrum of measurement, from brand to what I call hygiene-level demand creation.

Did you work with any outside partners?

We work with a team called John McNeil Studios, or JMS, based in Berkeley, California. They've been our agency of record for brand for the last three and a half years. JMS is a really talented group, and they help us with everything from television, to digital, to brand identity work. They get the category, and they're great partners.

In terms of launching the "Modern Software Factory" campaign and getting it to market, what were the biggest lessons learned?

I think the biggest lesson --- and it sounds so obvious -- is that when you keep the customer at the center of everything, it's your True North. We just kept coming back to, "How do they express their needs? Where do they place the greatest value?" It framed how we would tell the story, and what we would emphasize.

Continued here:
The Anatomy of a Global B2B Campaign - AdAge.com

An Explosive Grey’s Anatomy Finale! See How Meredith Reacts in the Moments After Blast – PEOPLE.com

Greys Anatomy has been known for letting sparks fly both figuratively and literally but things are taken up a notch in the season 13 finale on Thursday as the staff at Grey Sloane Memorial attempt to mitigate the casualties after an explosion rocks the hospital.

In an exclusive sneak peek, Meredith (Ellen Pompeo), Arizona (Jessica Capshaw) and Minnick (Marika Dominczyk) are in the Grey Sloane parking lot when a fireball is seen busting out of one of the higher floors of the hospital.

The doctors attempt to get back into the hospital but are stopped by security, who have locked the facility down while they hunt for a rapist on the run inside.

Bailey (Chandra Wilson) sees the women and insists the security guards allow the women inside so they can help with the crisis, which is the result of a fight between Pratt (Jerrika Hinton) and the rapist.

The season 13 finale of Greys Anatomy airs Thursday at 8 p.m. ET on ABC.

View post:
An Explosive Grey's Anatomy Finale! See How Meredith Reacts in the Moments After Blast - PEOPLE.com

Highlanders versus Dynamos: The anatomy of violence – NewsDay

Once again and not for the last time a Highlanders versus Dynamos football match ended in violence with the usual accusations and counter accusations of referee bias and oppression being the order of the day.

Candour: NQABA MATSHAZI

NQABA MATSHAZI

Highlanders fans are convinced there is a conspiracy against their team and have long noticed what they consider a pattern that referees are biased against them and playing against Dynamos is increasingly becoming a fruitless endeavour, as Bosso is handicapped even before the match begins.

On the other hand, Dynamos supporters question why Highlanders fans seem to always resort to violence when things do not go their way, which in the end will cost their team monetarily and ultimately the match.

While these are arguments that can go on until the cows come home, the reality is they are superficial and do not address the cause of the hostility between the supporters of the two teams.

The violence between the two sets of the teams supporters, I argue, is a microcosm of the countrys failure to unite and there is a clear tribal and regional schism, which finds expression during matches between Dynamos and Highlanders.

The build-up to the matches is often couched in tribal terms and is seen as a battle between the Shona and the Ndebele on one hand and while on the other, Dynamos is seen as the establishment team and Highlanders the opposite.

Sentiments that cannot be expressed in certain situations suddenly find space when Highlanders and Dynamos play and the result is always a tinderbox, which often results in violence.

For example, when the violence erupted at Barbourfields Stadium, I heard someone say, The Ndebeles have started, without realising the causal tribalism, which has become a hallmark when the two teams meet.

It goes without saying that for that person Ndebeles are associated with Highlanders and by extension, Shonas with Dynamos and this is what is tragic about Zimbabwe.

We are stuck in a tragic ethnic dichotomy, where we treat each other with suspicion, contempt and sometimes naked hatred, because we have failed to unite.

The only effort at addressing the anger that is bubbling beneath the surface was the 1987 Unity Accord, which increasingly looks farcical, which only brought Zapu and Zanu PF together but failed to deal with the ethnic tensions that continue to this day.

A big problem with Zimbabwe today is that we have adopted the ostrich mentality, where we hide our heads in the sand and pretend such issues do not exist and then we fail to address them, we act surprised when they spring up at football matches.

I saw one leaked WhatsApp message that said Highlanders fans were thugs and Gukurahundi should have wiped them out, quite a sick thing to say, but which could be instructive of our psyche as a nation.

For their part, Highlanders fans also have very nasty chants, where they accuse Dynamos fans Shonas of being complicit and active in the Gukurahundi killings, which reveals that even if we left the 1980s 30 years ago, there is still a festering wound that will not disappear because we pretend it did not happen.

It is also unhelpful that a State media columnist Nathaniel Manheru, known to be a senior civil servant gets acres of space in a public medium to refer to the 1980s killings as the so-called Gukurahundi, blatant denialism, which in other countries is criminalised.

While we can sit on the sidelines, pontificate and point fingers at who is responsible, the need for peace and reconciliation has never been so apparent and that is one way we can fix this broken country.

There is clearly discontentment among a section of the population and there is need to sit down and see how it can be addressed rather than treating the symptoms, which the fans violence is.

Parliament has haggled over the National Peace and Reconciliation Bill, which has been rejected at public meetings, but while the government dithers on this, the reality is that the nation continues to bleed from this division.

It is clear that the government does not want a Bill that will expose its violent past and I daresay, present and will do everything to frustrate it, but this does not help peace-building initiatives in the country and there will always be latent hostility and anger.

There is no appetite to address the Gukurahundi issue and this only creates hate and anger, which find expression in most unlikely places and perpetuates the cycle of violence, which has been an earmark of this country from independence to date.

It is not only Gukurahundi that needs addressing, there is the electoral violence of 1990, the food riots of 1998, the bloodletting of the 2002 and 2008 elections and Operation Murambatsvina of 2005, which need to be dealt with and ignoring all this is just papering over cracks that will continue to haunt generations to come.

This is not to excuse the violence at Barbourfields Stadium last Sunday, but rather to look at the root cause of why games between Highlanders and Dynamos are so emotion-filled and are likely to end prematurely.

What sometimes could be a genuine mistake by the officials is now seen through the lens of continued oppression and marginalisation of a tribe and the Matabeleland region.

Games between Highlanders and Dynamos are more than just football, they are political, and in the build-up to the games the discourse is dominated by politics rather than sporting issues.

As long as we have not dealt with the fundamentals, which revolve around genuine unity, peace and reconciliation, we can resign ourselves to the knowledge that more Highlanders and Dynamos games are likely to end prematurely and in violence.

The answer lies in our unresolved past.

Feedback: nmatshazi@southerneye.co.zw

Visit link:
Highlanders versus Dynamos: The anatomy of violence - NewsDay

A Yogurt a Day May Keep Disorders at Bay – Anti Aging News

Posted on May 17, 2017, 6 a.m. in Functional Foods GI-Digestive Inflammation

Researchers investigating the gut microbiome recommend that just as you should eat fiber every day, you should also follow suit with fermented foods.

Just about everyone loves yogurt. It tastes amazing, has a lovely texture and provides a number of health benefits. Yogurt is one of the many fermented foods that is fantastic for gut health. Researchers at the University of Nebraska-Lincoln are studying the nuances of the gut microbiome. The hope is that an improved understanding of the gut microbiome will help reduce the prevalence of heart disease, diabetes, and inflammatory disorders.

About Fermented Foods

Fermented foods are considered to be the original version of processed food. Fermentation allows for preservation to keep foods nutritious and tasty. Fermented foods have soared in popularity over the recent years as the general public became more interested in health food. Scientists continue to learn more about the important functions of microorganisms for digestion and overall health.

Aside from yogurt, examples of fermented foods and drinks include wine, beer, cheese, salami, fermented pickles, coffee, bread, and chocolate. These items are altered by helpful bacteria, fungi, and yeasts. These foods aresafe to consume for extended periods of time after the alteration. In many instances, fermentation makes the food that much more healthy and flavorful to boot.

About the Research

The research effort is being spearheaded by Robert Hutkins, an accomplished food science researcher. Maria Marco of the University of California is also leading the study. They are working in tandem with an international crew of scientists to determine if eating certain fermented foods like yogurt increases the number ofhelpful microorganisms.

Prior studies have proved that foods like yogurt, miso, and sauerkraut are tied to a reduced rate of diabetes, heart disease, gastrointestinal disorders and other health problems. Hutkins and a dozen other researchers are reviewing this data. He states that the data showsnumerous health benefits to consuming fermented foods like yogurt. He recommends that fermented foods should be included in all diets.

Hutkins' Background

Hutkins is affiliated with the Nebraska Food for Health Center. This group was established last year to study how gut microbes ward off disease and boost human health. It's food, animal and plant scientists work closely with medical experts to identify and develop foods that boost the human microbiome as well as the micro-organisms that reside in the gut. These scientists arefocused on developing foods that boost the body's immune system and metabolic processes.

About Microorganisms

Microorganisms within the gut are fed by the foods one consumes. Therefore it should come as no surprise that diet is an important factor that determines the functionality of the gut microbiome. This is an excellent opportunity to marry agriculture and medicine to alter how we think about warding off disease and treating disease. The hope is that improved knowledge of the main properties of fermentation methods will provide insights in terms of health benefits. However, at the current moment, only yogurt has been identified as a provider ofspecific health benefits. European health authorities made this recognition.

Hutkins' Findings

Hutkins and fellow researchers from the Netherlands, Canada, the United States, Ireland and France have encouraging findings following a thorough review of the latest research into fermented foods. Thegroup determined the increased interest in the impact of microbiomes on health justifies additional research along with clinical trials to study the functions of micro-organisms that reach the gastrointestinal tract via beverages and food.

Some of the studies within Hutkins' group show that yogurt consumption is tied to a decreased rates of diabetes. Additional research determined that beneficial relationships exist between yogurt and digestion, blood pressure, osteoporosis, and cholesterol. One particular study determined those who consume yogurt on a daily basis were less irritable.

See the original post here:
A Yogurt a Day May Keep Disorders at Bay - Anti Aging News

Students Present Biochemistry Research in Chicago – Marymount Manhattan College News

Three MMC Biology and Biomedical Sciences students presented their research at the international Experimental Biology Meeting (EB 2017) in Chicago this April.

Elevit Perez 17, Taylor Allen 17, and Tracy Tauro 18 presented their research projects at the Experimental Biology meeting held in Chicago, IL, on April 22-25, 2017. All three students are conducting research with Dr. Benedetta Sampoli Benitez, Professor of Chemistry and Biochemistry. In particular, Perez and Tauro presented a poster titled Understanding conformational changes during translesion synthesis:in silicostudies of DinB. Allen presented a poster on Investigating the mechanism of trans-lesion synthesis by human DNA polymerase kappa. Both research projects were faculty-supervised collaborations conducted at MMC with funding from the Rose M. Badgeley Residuary Charitable Trust Grant.

The Experimental Biology meeting is one of the largest meetings in Biology, with more than 14,000 participants. Six societies in Biology join in the meeting, including the American Society for Biochemistry and Molecular Biology (ASBMB), of which our undergraduate program has a chapter. Students presented both at the undergraduate poster event on Saturday and at the general meeting the following day, giving them tremendous exposure to scientific presentations.

Follow this link:
Students Present Biochemistry Research in Chicago - Marymount Manhattan College News

Veterinary Biochemistry Analyzers Market in Global Industry : Development and Forecast 2023 – MilTech

Veterinary Biochemistry Analyzers Market: Overview

Veterinary biochemistry analyzers enable testing to be performed quickly and accurately for immediate diagnosis and health check for animals. They are also used in emergency situation, and routine testing. Increasing incidences of disease outbreak in animals and technological advancements are expected to drive the veterinary biochemistry analyzers market. Additionally, growing awareness regarding animal health and rise in investment opportunities together form strong market prospects for veterinary biochemistry analyzers, especially in the developing countries.

View Report @ http://www.transparencymarketresearch.com/veterinary-biochemistr

The threats such as foot and mouth disease (FMD), as well as agents that affect animals and humans, such as bovine tuberculosis and paratuberculosis, anthrax, avian influenza, bovine spongiform encephalopathy (BSE) and West Nile virus are responsible for rise in importance of need for veterinary disease diagnostics eventually propelling the market growth.

Most veterinary laboratories typically provide a basic panel of tests. The veterinary biochemistry analysis may be performed in-house at the veterinarians clinic or at a specialized test facility in another location depending on the need of test type to be performed as well as availability of equipment in that particular facility. Advancements in the analyzers technology is anticipated to fuel fueled the market growth due to the availability of faster and cheaper microchips with increase in acceptance level of pet owners for laboratory testing.

Veterinary Biochemistry Analyzers Market: Segmentation

The global veterinary biochemistry analyzers market can be segmented on the basis of product type, test type, animal type, end-users and geography. Test types include clinical chemistry, critical care and blood gases, electrolytes, glucose, lactate and blood and urine tests. Other tests include: tests for anemia, endocrine function; cancer, viral pathogens such as calicivirus (CaCV), canine adenovirus type-1 (CAV-1), coronavirus, adenovirus, parvovirus, rotavirus, rabies, West Nile Virus, etc.; and bacteria and parasites such as E. coli, heartworm, cryptosporidia, hookworm, leptospirosis, leishmania, Lyme disease, tapeworm and roundworm. Chemical analysis of urine may include determination of specific gravity and pH level, measurement of the amount of glucose, protein, or fragmented blood cells, assisting in identification of injury, disease, or defects.

Analysis of the numbers and structure of blood cells is important in the diagnosis and monitoring of disease and infection. Blood samples are usually taken by the veterinarian or a veterinary technician for analysis. Product types include fully automated analyzers, semi-automated analyzers, hematology analyzers, urine analyzers amongst others.

End-users segment includes veterinary clinics, pet hospitals and animal research institutes. Companion animal and farm animal form two segments for animal type.

Veterinary Biochemistry Analyzers Market: Region-wise Outlook

Geographically, the veterinary biochemistry analyzers market across the globe can be segmented into four major regions, namely, North America, Europe, Asia Pacific and Rest of the World. North America is expected to lead the market with maximum share followed by Europe attributed to the increasing companion animal population and positive trends towards healthcare expenditure for animals in these regions.

Veterinary Biochemistry Analyzers Market: Key Entities

Major players contributing to the global veterinary biochemistry analyzers comprise Abaxis,Inc., Heska, Diagno-Vision Products Corporation, Idexx Laboratories, Inc., Mindray Medical International Limited, Neogen Corporation, Thermo Fischer Scientific, Virbac SA, Woodley Equipment Company Ltd., Zoetis, Inc.

Get accurate market forecast and analysis on the Veterinary Biochemistry Analyzers Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag

Univerities such as the University of Minnesota Veterinary Diagnostic Laboratory (VDL), which is fully accredited by the American Association of Veterinary Laboratory Diagnosticians, provide quality diagnostic services such as bacteriology, necropsy, electron microscopy, serology, clinical chemistry, histopathology, endocrinology, virology, immunohistochemistry, parasitology, toxicology and molecular diagnostics. VDL is also engaged in training future diagnosticians and veterinarians.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMRs experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMRs syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Read the rest here:
Veterinary Biochemistry Analyzers Market in Global Industry : Development and Forecast 2023 - MilTech

Is the Hospital Going to Explode on Grey’s Anatomy? – POPSUGAR

15 Shares

Chat with us on Facebook Messenger. Learn what's trending across POPSUGAR.

Not to alarm you or anything, but we may have blown this year's Grey's Anatomy finale wide open. As you might recall, the penultimate episode of the season comes to an explosive end when Stephanie inadvertently causes an oxygen tank to explode. You know, after setting that crazy stalker rapist on fire. While this has us wondering if Stephanie is dead or alive, it could have even graver implications when it comes to the season finale. Back in March, we already got a few details about the episode. Jessica Capshaw told us that it would be "quite explosive," while Chandra Wilson said it would be "big and loud and strong." Are you sensing where we're going with this?

We have a feeling the whole hospital is going to explode. It's not unreasonable. After all, there's already been a huge explosion in one wing. The finale could show the entire cast in crisis, trying desperately to put out fires and save lives. But what if they can't control the fire in time? The episode is called "Ring of Fire." What if the fire overwhelms the hospital while all the other doctors are inside? What if, in the final moments, Grey Sloan Hospital explodes? If you have any doubts, just know this: Shonda Rhimes came up with the idea way back in 2009.

what if at the end of this season of Grey's Anatomy, the hospital just exploded into flames and we don't know who lives or who dies?

shonda rhimes (@shondarhimes) March 9, 2009

See you on Thursday. We'll bring tissues.

Beauty Tips

12 Mistakes All Natural-Hair Newbies Need to Avoid

by Solenne Kamba 6 hours ago

Food Video

Cinderella Works Her Magic on This Pumpkin Pie

by Megan Lutz 1 week ago

Politics

Sally Yates Will Not Pardon the Manterruption

by M'Ballu Tejan-Sie 6 days ago

Summer Beauty

The Only 9 Sunscreens Your Body Needs This Summer

by Krista Jones 8 hours ago

Once Upon a Time

5 Major Stars Are Leaving Once Upon a Time Along With Jennifer Morrison

by Kelsie Gibson 4 days ago

Kourtney Kardashian

Kim Kardashian's Brutally Honest Tweets About Her Vacation Are F*cking Wild

by Quinn Keaney 3 weeks ago

Spring Beauty

These Are 23 of the Hottest Beauty Launches For May 2017

by Lauren Levinson 13 minutes ago

Camilla Luddington

Grey's Anatomy's Camilla Luddington Welcomes a Baby Girl

by Kelsie Gibson 4/11

Food News

The Internet Is Having a Friggin' Field Day Dissing the Unicorn Frappuccinos

by Anna Monette Roberts 3 weeks ago

Get the Dish

This Sunny Dessert Is Like a Beachy Vacation in a Cup

by Brandi Milloy 1 day ago

Celebrity Feuds

Taylor Swift's Ex Confirms That He's Working With Her Nemesis

by Brittney Stephens 6 days ago

Chris Pratt

Chris Pratt's Reaction to Trump Firing the FBI Director Is Absolutely Perfect

by Laura Marie Meyers 6 days ago

View post:
Is the Hospital Going to Explode on Grey's Anatomy? - POPSUGAR

ABC fall 2017 lineup: ‘Grey’s Anatomy’ spinoff, ‘Good Doctor,’ more – Newsday

ABC will spin off series from three franchises next season Greys Anatomy, The Bachelor and Dancing With the Stars and add yet another Marvel-based drama, the network announced Tuesday.

The Greys spinoff will be set in a Seattle firehouse, with characters introduced on the flagship series next season. In addition, The Bachelor Winter Games will cast past contestants in a series with winter-themed athletic challenges including the toughest sport of all, love.

Then this: Dancing With the Stars Junior will pair celebrity kids and kids of celebrities with professional junior ballroom dancers. No airdates set, but the reality series will premiere next year.

ABC executives also said the network will air a live comedy special produced by Jimmy Kimmel and Justin Theroux featuring comics reading scripts from classic sitcoms.

Heres the fall lineup:

Monday: Dancing With the Stars (8); The Good Doctor (10), with Freddie Highmore as a surgeon with autism and savant syndrome.

Tuesday: The Middle (8); Fresh Off the Boat (8:30); black-ish (9); The Mayor (9:30), about a rapper (Brandon Micheal Hall) who becomes mayor (its produced by Daveed Diggs of Hamilton); The Gospel of Kevin (10), with Jason Ritter and JoAnna Garcia Swisher, about a guy on a mission to save the world.

Wednesday: The Goldbergs (8); Speechless (8:30); Modern Family (9); American Housewife (9:30); Designated Survivor (10).

Thursday: Greys Anatomy (8); Scandal (9); How to Get Away With Murder (10).

Friday: Once Upon a Time (8); Marvels Inhumans (9), about Black Bolt (Anson Mount) he with the very loud voice and his family of Inhumans; 20/20 (10).

Saturday: College football

Sunday: Americas Funniest Home Videos (7); To Tell the Truth (8); Shark Tank (9); Ten Days in the Valley (10), with Kyra Sedgwick as a news producer whose child goes missing.

Link:
ABC fall 2017 lineup: 'Grey's Anatomy' spinoff, 'Good Doctor,' more - Newsday

RSC Carbohydrate Chemistry Award – Royal Society of Chemistry

Outstanding, inspirational

In nominating her, Professor Timothy Gallagher from the University of Bristol said: "Carmen has established a very successful and internationally recognized independent research programme, as evidenced by over 55 publications in high profile journals that are becoming well-cited, and a string of conference invitations.

"Her independent research is characterised by its breadth and collaborative dimension, spanningcarbohydrate synthesis through to the application of oligosaccharides in glycobiology.

"It is clear that Carmen is a scientist who has already achieved a great deal and possesses very significant future potential. Her track record is outstanding, and her ability to juggle a complicated and demanding series of roles is inspirational."

Dr Galan is a Reader in organic and biological chemistry at the University of Bristol, where she holds an ERC Consolidator award and an EPSRC Career Acceleration Fellowship. She undertook her PhD with Prof Geert-Jan Boons at the Complex Carbohydrate Research Centre in Georgia, USA before postdoctoral studies with Prof Chi-Huey Wong (Scripps Research Center) and Prof Sarah OConnor (MIT).

She is a member of editorial advisory boards for Organic and Biomolecular Chemistry, RSC Advances and the editorial boards of Carbohydrate Research and Nature Scientific Reports. She also represents the United Kingdom in the International Carbohydrate Organisation.

See the original post:
RSC Carbohydrate Chemistry Award - Royal Society of Chemistry

BIO Statement on the Passing of Biotechnology Giant Henri Termeer … – Business Wire (press release)

WASHINGTON--(BUSINESS WIRE)--Henri Termeer, who passed away at the age of 71, was a founding father of modern biotechnology. He brought to his work, and to his life, a passion, a vision and a perseverance to bring ground-breaking medical innovations to those suffering from rare diseases.

Through his work, Termeer became a mentor and a role model for biotechnology entrepreneurs around the globe. The culture he created at Genzyme, and at the various institutions he worked for throughout his career, was widely seen as the gold standard for patient-focused drug development. He was a master at creating cultures where great science and great people could flourish. As the Boston Globe aptly noted, Termeer had magnetism and warmth, and a deft ability to harness top talent toward a common goal.

Termeer, who was a larger-than-life figure across the biotechnology field, was instrumental in the founding of BIO in 1993, serving as its first vice chair for health. He was named Chairman of the organization in 1996. During his tenure as Chair of BIO, and in the years that followed, Termeer was a key catalyst in the growth of the organization and in establishing BIOs position at the forefront of key policy and regulatory debates. He was an active member of BIOs Board of Directors since its founding until his death, with only a short break in his tenure. Termeer served on BIOs Executive Committee from 1993 to 2000.

Following are statements from leadership at the Biotechnology Innovation Organization (BIO):

Few people in our industry have had as profound an impact as Henri Termeer on the science of biotechnology and the patients who depend on it, said Jim Greenwood, President and CEO of BIO. He had a unique ability to inspire the men and women around him. Henri certainly was a brilliant businessman and a charismatic leader, but his burning passion was to do the unthinkable to innovate and to treat and cure rare diseases that others believed too difficult to tackle. Henri's love of his profession and the people in it was contagious. He taught us that even though our companies were sometimes competitors, our industry must speak with a united voice in the corridors of power. He was a founding father of BIO and thus the thriving ecosystem the biotechnology community enjoys today is another central part of his legacy. Henri was admired, respected and loved by all of us who were fortunate enough to know him as a colleague, a teacher, and a friend. He is an irreplaceable talent who will be long remembered and sorely missed.

Henri Termeer was a giant, said Ron Cohen, President & CEO of Acorda Therapeutics and Chair of BIO. He has left us much too soon. High among his many legacies are the tens of thousands of patients and their families who have benefited from Genzymes innovations, and the scores of biotechnology professionals whom he mentored and who have gone on to be leaders at other companies.

I had the honor of having worked at Genzyme and calling Henri Termeer amentor, said Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Vice Chair of BIO. He taught us all to be tough and business minded, while simultaneously taking into account how every decision impacted every person in the organization that was part of making Genzyme what it was. His focus on always doing the right thing for people and the business was something truly special. We all lost a great friend, a great mentor and awonderful role model.

From 1993-1998, Hastings served as Vice President, Global Marketing, Genzyme Therapeutics, President of Genzyme Europe and President of Genzyme Therapeutics.

"Henri has left us far too soon, but his legacy and contributions to our industry and patients with rare diseases will last forever, said John Maraganore, CEO of Alnylam Pharmaceuticals. Indeed, Henri pioneered the advancement of innovative medicines for orphan disease and inspired other companies and entrepreneurs to follow. He will be deeply missed."

"As an industry leader Henri was unparalleled and unrivaled, said Jeremy Levin, chairman and CEO of Ovid Therapeutics. As a mentor and friend, he was a foundational component of my business philosophy and career. He will be mourned and deeply missed but never forgotten."

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

See the original post here:
BIO Statement on the Passing of Biotechnology Giant Henri Termeer ... - Business Wire (press release)

Anatomy of a Song: ‘Smoke on the Water’ – Wall Street Journal (subscription)


Wall Street Journal (subscription)
Anatomy of a Song: 'Smoke on the Water'
Wall Street Journal (subscription)
Along with Blue Cheer, Led Zeppelin and Black Sabbath, Deep Purple helped pioneer heavy metal in the early 1970s. The British band's Smoke on the Water, with its commanding guitar-riff opener, remains one of metal's most enduring anthems.

See the article here:
Anatomy of a Song: 'Smoke on the Water' - Wall Street Journal (subscription)

3 Best Stocks in Personalized Medicine – Motley Fool

Personalized medicine, also known as precision medicine or genomic medicine, is one of the most revolutionary trends shaping the future of healthcare. What is personalized medicine? The simple definition is that it's the customization of care to an individual's genetic profile. Several publicly traded companies stand out as leaders in the field.

Exact Sciences (NASDAQ:EXAS), Illumina (NASDAQ:ILMN), and Vertex Pharmaceuticals (NASDAQ:VRTX) are pioneers in personalized medicine -- each in a different way. Here's why I think these are the three best stocks in personalized medicine right now.

Image source: Getty Images.

Exact Sciences markets the CologuardDNA screening test for colorectal cancer. Cologuard has enjoyed the strongest product launch of any diagnostic test ever, with more than 450,000 people screened since late 2014. But there's much more potential growth. There are around 80 million patients in the U.S. alone who need to be tested for colorectal cancer, but many don't get tested because they don't want a colonoscopy. Exact Sciences hopes to capture around 30% of that market.

Cologuard should continue to drive Exact Sciences stock higher in the near future, but over the long run there are even more opportunities. Exact Sciences is collaborating with the Mayo Clinic to develop a platform for early detection of cancer by identifying DNA methylation markers. (Addition of methyl groups to DNA changes gene expression and potentially lead to cancer.) Significant progress has already been made in what could be a huge new market for Exact Sciences.

Although Exact Sciences isn't profitable yet, it's headed in the right direction. Analysts project the company will grow earnings by an average annual rate of 68% over the next five years. That seems quite possible with Cologuard continuing to pick up momentum.

Illumina is the leader in genomic sequencing, an essential tool that makes the personalized medicine revolution possible. The company began operations in 1998 and launched its first DNA sequencing system in 2007. Since then, Illumina's technological innovations havereduced the cost of sequencing by a factor of more than 10,000 and have reduced sequencing time per gigabase by a factor of approximately 3,500.

The company is continuing its track record of innovation with its recent launch of the NovaSeq sequencing system. Illumina thinks that the NovaSeq architecture could lead to reducing the cost of human genome mapping to $100, which would open up genomic sequencing to more customers than ever before. Selling more systems would be great news for Illumina, but the added consumables revenue would be even better: The company makes around two-thirds of its total revenue from consumables sales.

As a well-established company now, Illumina might not enjoy the tremendous growth that it did in the early days of genomic sequencing. However, Wall Street analysts still estimate that Illumina will grow earnings by an average annual rate of 14% over the next several years, thanks in large part to great prospects for NovaSeq.

Vertex Pharmaceuticals is leading the way in the use of personalized medicine to fight cystic fibrosis (CF). The company won U.S. regulatory approval in 2012 for its first drug, Kalydeco, as a treatment for CF patients with theG551D mutation. Another approval came in 2014 for CF patients with one of 10 other genetic mutations.In 2015, Vertex received approval for Kalydeco in treating children ages two to five with specific gene mutations that cause CF.

While Kalydeco has been successful, Vertex's biggest opportunities lie with other CF drugs. Vertex is still finalizing reimbursement arrangements in several European nations for Orkambi, but Orkambi has already become the company's top-selling product. Even greater prospects could be in store for a combination of Kalydeco and tezacaftor, for which Vertex plans to file for approval in the third quarter of 2017.

Analysts think that Vertex can grow its earnings by nearly 65% annually over the next five years. Although the stock looks expensive right now with shares trading at 39 times expected earnings, Vertex remains a good pick for investors with that kind of growth potential.

Keith Speights has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

See the rest here:
3 Best Stocks in Personalized Medicine - Motley Fool

Chemistry (relationship) – Wikipedia

In the context of relationships, chemistry is a simple "emotion"[1] that two people get when they share a special connection. It is not necessarily sexual. It is the impulse making one think "I need to see this [other] person again" - that feeling of "we click".[2] It is very early in one's relationship that they can intuitively work out whether they have positive or negative chemistry.[3]

While the actual definition of chemistry, its components, and its manifestations are fairly vague, this is a well documented concept. Some people describe chemistry in metaphorical terms, such as "like cookie dough and vanilla ice cream", or "like a performance".[4] It can be described in the terms of mutual feelings - "a connection, a bond or common feeling between two people", or as a chemical process - "[it] stimulates love or sexual attraction...brain chemicals are definitely involved".[3] While chemistry has been described as "that romantic spark between [two people]", the term "spark" in the context of relationships is as vague as "chemistry", and therefore is not particularly useful in a definition.[1] It has also been described as "intangible, unspoken [and] energetic".[5] Chemistry is an unconscious decision, informed by a complex blend of criteria.[2]

Some of the core components of chemistry are: "non-judgment, similarity, mystery, attraction, mutual trust, and effortless communication"[3] Chemistry can be described as the combination of "love, lust, infatuation, and a desire to be involved intimately with someone".[2]

Research by Kelly Campbell, Ph.D., suggests that "not everyone experiences chemistry". She decided that "chemistry occurred most often between people who are down-to-earth and sincere". This is because "if a person is comfortable with themselves, they are better able to express their true self to the world, which makes it easier to get to know them...even if perspectives on important matters differed." Sharing similarities is also deemed essential to chemistry as "feeling understood is essential to forming relational bonds."[3]

In general terms, there are 3 main types of chemistry, which are defined in terms of the nature of the rapport between the respective people:[6]

The various manifestations of chemistry are: sexual chemistry, romantic chemistry, emotional chemistry, activity chemistry, team performance chemistry, creative chemistry, intellectual chemistry, and empowerment chemistry".[6]

There are various psychological, physical and emotional symptoms of having good chemistry with another person. It has been described as a "combination of basic psychological arousal combined with a feeling of pleasure". The nervous system gets aroused, causing one to get adrenaline in the form of "rapid heartbeat, shortness of breath, and sensations of excitement that are often similar to sensations associated with danger". Other physical symptoms include "blood pressure go[ing] up a little, the skin...flush[ing], the face and ears...turn[ing] red and...[a] feeling of weakness in the knees". One can feel a sense of obsession over the other person, longing for "the day [when they return] to that person". One can also uncontrollably smile whenever thinking about the other person.[3]

There is some debate over whether one can artificially create chemistry if they are "not initially feeling it". While some people hold that it is something that you "can't learn and can't teach...[and you] either have...or you don't", others hold that chemistry is a process rather than a moment, "build[ing] up and adds up and eventually you get this kind of chemical bonding". Some people, while believing it is possible to artificially create chemistry, think that it is better to let chemistry hit them spontaneously.[3]

In Western Society, chemistry is generally considered the "igniter [and] catalyst for the relationship", i.e., without this chemistry, there can be no relationship.[3] Having chemistry "can be the difference between a relationship being romantic or platonic". Chemistry "can cause people to act sexually impulsively or unwisely". It can also be the difference between someone remaining faithful in their relationship, and seeking one night stands and affairs.[1]

Romantic chemistry can be one of the most dangerous and self destructive emotions if left unchecked. Some people will enter relationships with incompatible mates blinded by chemistry. Chemistry often seems to have the power to blind us. Chemistry is the reason the saying, "Love is blind," exists. Chemistry can make otherwise rational people ignore serious problems and issues in an individual and relationship. Chemistry often blinds people to warning signs that a person or relationship is not healthy or the right one for them.

Dating coach Evan Marc Katz suggests that "chemistry is one of the most misleading indicators of a future relationship. Chemistry predicts nothing but chemistry." This is because chemistry can make people blind to actual incompatibilities or warning signs. Psychologist Laurie Betito notes that arranged marriages actually do quite well in terms of relationship satisfaction, and this is because "a spark can build based on what you have in common. You can grow into love, but you grow out of lust."[7]

Neil Clark Warren argues that physical chemistry is important because "couples who don't share strong chemistry may have additional problems during the ups and downs of a life together." Like Betito, he suggests not ruling someone out on the first date due to lack of chemistry. "But," he adds, "if by the second or third date you dont feel a strong inclination to kiss the other person, be near him, or hold his hand, youre probably never going to feel it."[8]April Masini likewise says that chemistry is a strong predictor of relationship success. She suggests that chemistry comes and goes, and it's important to actively cultivate it because it can help couples deal with future conflicts.[9]

See more here:
Chemistry (relationship) - Wikipedia

Panel Woes For Puma And Statistical Uncertainties For Emmaus – Seeking Alpha

Welcome to your weekly digest of approaching regulatory and clinical readouts. Puma's (NYSE:PBYI) breast cancer project neratinib will go before a US panel on May 24, but Roche's (OTCQX:RHHBY) rival Perjeta could soon show clinical data that render neratinib almost irrelevant, and the recent departure of a senior member of Puma's staff has fueled rumors of a negative outcome at the adcom.

On the same day Emmaus Life Sciences will go before the same FDA panel for its sickle cell disease project Endari, currently availbale as a nutraceutical. Regulators have questioned the efficacy analysis in the past, but with few options for patients approval could still ensue.

Puma becomes the prey

In just over a week a panel will discuss Puma's neratinib for use as an adjuvant treatment in Her2-overexpressing breast cancer. The filing was based on the phase III Extenet trial, in which patients received neratinib monotherapy after a year's Herceptin.

Puma has a number of hurdles in its path, the biggest of which is Perjeta. A positive result in Roche's phase III Aphinity study indicated that Perjeta could potentially be practice-changing for breast cancer, and Puma's shares dropped 14% (Aphinity all but confirms Puma's worst nightmare, March 2, 2017).

Roche's trial gave patients Perjeta plus Herceptin for a year versus Herceptin alone. Details, including the extent of Perjeta's benefit, will appear at Asco on June 5.

Other issues for Puma include the severe diarrhea seen with neratinib, questions over neratinib's marginal benefit in Extenet trial, and large numbers of patients being censored.

This week Puma shares took another tumble on the news that its senior vice-president of regulatory affairs, Dr. Robert Charnas, would step down. Speculation that the resignation could be linked with the upcoming panel meeting, rather than the health reasons cited in the company's 8-K, caused shares to fall 16%.

Neratinib sales are forecast to reach $809m by 2022, according to sellside consensus from EvaluatePharma, but just over a year ago these sat at $2bn. Neratinib's PDUFA date is set for July; a strong benefit with Perjeta could be hard for the FDA to ignore.

Lacking options

Emmaus Life Sciences' Endari, in sickle cell disease, will also face the panel on May 24, and has a PDFUA date set for July 7.

The Californian group says that if Endari is approved it will become the first treatment for pediatric patients and the first new therapy in nearly 20 years for adult patients. However, it does not treat the underlying cause of the disease, instead aiming to reduce the frequency of the episodes of pain called sickle cell crises. It has orphan drug designation in the US and EU and US fast-track designation.

Endari is said to work by reducing oxidative damage to red blood cells. It consists of the amino acid L-glutamine as a nutritional supplement - the same active ingredient as the company's Nutrestore nutraceutical, available for short bowel syndrome in combination with recombinant human growth hormone. Endari is filed as a drug under the 505(b)(2) pathway.

The phase III trial was conducted in 230 patients aged five and over. It tested 0.3g/kg of L-glutamine twice daily for 48 weeks, up to a daily limit of 30g. The powder is mixed with water or certain non-heated foods.

The placebo comparator was the food additive maltodextrin, and two thirds of patients were on background hydroxyurea treatment, an established drug used to reduce crises. The company reported a 25% reduction in the median frequency of sickle cell crises, with Endari patients having a median of three over the 48-week trial.

Initially the company reported a p value of 0.063, above the pre-specified p value of 0.045. However, using a different analysis it said the results were "highly statistically significant" at 0.005.

The FDA had raised concerns over the primary endpoint analysis after the data were initially unblinded in 2014. Emmaus provided a report by an independent statistician explaining the significant results using the modified Ridit method, adjusting for varying strata or subgroup size, which in this case was region and hydroxyurea use.

No doubt the panel meeting will pay close attention to the statistical analyses used.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Read more:
Panel Woes For Puma And Statistical Uncertainties For Emmaus - Seeking Alpha

Giacomo Gianniotti’s wayward youth helped bring Canadian to Grey’s Anatomy – Toronto Star

Giacomo Gianniotti just finished his 50th episode acting in one of TVs most durable hits, Greys Anatomy: a heady position for a young Canadian actor. He's inclined to thank marijuana for getting him to this stage in life.

I guess Im really happy for pot, says the actor, smiling, during a Skype chat. Because if I hadnt smoked it . . . I wouldnt have gone to Toronto and stepped into the me that I was meant to be.

Gianniotti, 27, has been a regular on Greys, now in its 13th season, playing Dr. Andrew DeLuca since 2015. You may have caught him on the big screen in last years Stephen Hopkins film Race; hes also enjoyed stints on shows including Reign, Selfie and Murdoch Mysteries.

And it all began, he supposes, in Grade 9 in Parry Sound, when he was caught smoking marijuana. He was kicked out of school and moved to Toronto to live with his dad, where he attended Cardinal Carter Academy for the Arts.

In high school, he recalls, he would break into the Kraft Canada headquarters parking lot in North York with his buddies.

Wed have coffee and cigarettes and just talk, says Gianniotti. (There) was this beautiful view of the Don Valley Parkway.

Sometime after Cardinal Carter, he enrolled in Humber Colleges theatre program, during which time he set up shop with some pals in Parkdale in a horrible apartment with cockroaches. It was a far cry from his childhood back in Parry Sound (everybody left their doors open, you shared food with your neighbours, he recalls), but Toronto is where his acting career began.

Before long, though, he was looking south. Greys Anatomy was in its early years when Gianniotti was in high school. The girls at his school watched, but hed never seen it. Fast forward, a bunch of years later . . . I sent a tape out for this Greys Anatomy character.

Four months went by and he hadnt heard back. Gianniotti had begun to feel frustrated with the small pool of acting options in Toronto and he decided to move to Los Angeles.

Driving across America with two Toronto friends who were helping him relocate, he got a call from his agent, telling him that Greys Anatomy creator Shonda Rhimes a huge figure in the TV industry wanted to meet with him when he arrived in L.A.

The three men were in Albuquerque and Gianniotti told his friends to take over driving for the rest of the way. In the back of the car he studied his script. When he arrived in L.A., he met with Rhimes and her team a few days later, he had the part.

Joining the show was at first overwhelming.

It was a lot of people, a lot of personalities . . . its hard to get quiet, says Gianniotti.

And quiet is important for the actor, who calls himself really shy and really introverted. He uses his headphones to block out some of the noise on set and he has guitars in his trailer, which he plays to unwind.

But hes found a kindred spirit in actor Martin Henderson, who plays Ellen Pompeos new love interest, cardiothoracic surgeon Dr. Nathan Riggs.

Hes from New Zealand and Im from Canada, and weve just drawn a lot of parallels of being mountain men and liking the outdoors, Gianniotti says of his off-set friend.

Getting used to new environments is nothing novel to the blue-eyed Italian-Canadian, who was born in Rome to an Italian father and a Canadian mother, and moved to this country when he was around 5 years old. But he had a lot to learn, it emerged, about one of the staples of his new job: simulating surgery.

Theres just so much protocol in the OR, he says, recalling that one medical producer was especially exasperated with him that first day.

Shes like, If a doctor saw you, they would be like, faker! he says with a laugh. And we dont want that, so my first surgery every two seconds, she was like Cut! Giacomo! What are you your hands are no! oh my God!

It was a little bit of a learning curve and (the other actors were) laughing at me, he chuckles. Because they had all been there themselves and were remembering it.

His character was most recently at the centre of a dramatic, violent encounter with Alex Karev (Justin Chambers), which almost sent the latter (a fan-favourite character) to jail. Gianniotti is excited for fans to see the season finale, which he describes as huge and wild and big-budget, but laments that theres just so many amazing things (about it) and I cannot tell you any of them!

The eventfulness of the deathless Greys is probably one key to its success; the show gained teen viewers last year while staying in the top 10 among TV watchers aged 18 to 34 for the sixth year running, according to ABC. Gianniotti cant comment yet on whether hell be back on the show next season; his own contract is managed yearly and he hasnt received it yet.

How has his life been changed by the gig?

I didnt have much growing up. Im so grateful for what I have now and its kind of ridiculous, to be honest, he admits.

But the actor often talking with his hands during the interview or absent-mindedly stroking his beard doesnt see the point in spending money on material effects.

I dont buy fancy things . . . I have, like, three pairs of jeans, he says.

But he can make a difference for those who are struggling; his platform allows him to call out to fans and quickly raise money for the causes he believes in. Recently hes put a lot of his heart into working with an L.A. charity for homeless youth called My Friends Place.

Its such a massive problem. Literally everywhere you look (in Los Angeles you see a homeless person) . . . and its usually a kid.

He misses Toronto for example, snow, the lakeshore, and getting macaroons and coffee at Queen Wests Nadge before strolling through Trinity Bellwoods. In fact, he returned to town in April to direct a music video for those friends who helped him move to L.A. years ago.

Hes also started his own production company and recently wrote a song, which he tells fans to expect in the next couple of months. He has broader ambitions for his acting career, too, declaring hes dying, dying, dying to explore war films.

Until that offer arrives, I ask him how he has time for it all. Not a lot of sleep, he quips.

Greys Anatomys Season 13 finale airs Thursday, May 18 at 7 p.m. on CTV.

Follow this link:
Giacomo Gianniotti's wayward youth helped bring Canadian to Grey's Anatomy - Toronto Star